PURPOSE: In a prospective study, Consequences of Prolonged Febrile Seizures in Childhood (FEBSTAT), we determined the frequency of human herpesvirus (HHV)-6 and HHV-7 infection as a cause of febrile status epilepticus (FSE). METHODS: Children ages 1 month to 5 years presenting with FSE were enrolled within 72 h and received a comprehensive assessment including specimens for HHV-6 and HHV-7. The presence of HHV-6A, HHV-6B, or HHV-7 DNA and RNA (amplified across a spliced junction) determined using quantitative polymerase chain reaction (qPCR) at baseline indicated viremia. Antibody titers to HHV-6 and HHV-7 were used in conjunction with the PCR results to distinguish primary infection from reactivated or prior infection. KEY FINDINGS: Of 199 children evaluated, HHV-6 or HHV-7 status could be determined in 169 (84.9%). HHV-6B viremia at baseline was found in 54 children (32.0%), including 38 with primary infection and 16 with reactivated infection. No HHV-6A infections were identified. HHV-7 viremia at baseline was observed in 12 children (7.1%), including eight with primary infection and four with reactivated infection. Two subjects had HHV-6/HHV-7 primary coinfection at baseline. There were no differences in age, characteristics of illness or fever, seizure phenomenology or the proportion of acute EEG or imaging abnormalities in children presenting with FSE with or without HHV infection. SIGNIFICANCE: HHV-6B infection is commonly associated with FSE. HHV-7 infection is less frequently associated with FSE. Together, they account for one third of FSE, a condition associated with an increased risk of both hippocampal injury and subsequent temporal lobe epilepsy. Wiley Periodicals, Inc.
PURPOSE: In a prospective study, Consequences of Prolonged Febrile Seizures in Childhood (FEBSTAT), we determined the frequency of humanherpesvirus (HHV)-6 and HHV-7 infection as a cause of febrile status epilepticus (FSE). METHODS:Children ages 1 month to 5 years presenting with FSE were enrolled within 72 h and received a comprehensive assessment including specimens for HHV-6 and HHV-7. The presence of HHV-6A, HHV-6B, or HHV-7 DNA and RNA (amplified across a spliced junction) determined using quantitative polymerase chain reaction (qPCR) at baseline indicated viremia. Antibody titers to HHV-6 and HHV-7 were used in conjunction with the PCR results to distinguish primary infection from reactivated or prior infection. KEY FINDINGS: Of 199 children evaluated, HHV-6 or HHV-7 status could be determined in 169 (84.9%). HHV-6B viremia at baseline was found in 54 children (32.0%), including 38 with primary infection and 16 with reactivated infection. No HHV-6A infections were identified. HHV-7 viremia at baseline was observed in 12 children (7.1%), including eight with primary infection and four with reactivated infection. Two subjects had HHV-6/HHV-7 primary coinfection at baseline. There were no differences in age, characteristics of illness or fever, seizure phenomenology or the proportion of acute EEG or imaging abnormalities in children presenting with FSE with or without HHV infection. SIGNIFICANCE: HHV-6B infection is commonly associated with FSE. HHV-7 infection is less frequently associated with FSE. Together, they account for one third of FSE, a condition associated with an increased risk of both hippocampal injury and subsequent temporal lobe epilepsy. Wiley Periodicals, Inc.
Authors: James M Provenzale; Daniel P Barboriak; Kevan VanLandingham; James MacFall; David Delong; Darrell V Lewis Journal: AJR Am J Roentgenol Date: 2008-04 Impact factor: 3.959
Authors: Darrell V Lewis; Daniel P Barboriak; James R MacFall; James M Provenzale; Teresa V Mitchell; Kevan E VanLandingham Journal: Prog Brain Res Date: 2002 Impact factor: 2.453
Authors: Caroline Breese Hall; Mary T Caserta; Kenneth C Schnabel; Michael P McDermott; Geraldine K Lofthus; Jennifer A Carnahan; Lynne M Gilbert; Stephen Dewhurst Journal: J Infect Dis Date: 2006-03-06 Impact factor: 5.226
Authors: D Donati; N Akhyani; A Fogdell-Hahn; C Cermelli; R Cassiani-Ingoni; A Vortmeyer; J D Heiss; P Cogen; W D Gaillard; S Sato; W H Theodore; S Jacobson Journal: Neurology Date: 2003-11-25 Impact factor: 9.910
Authors: Mary T Caserta; Caroline B Hall; Richard L Canfield; Philip Davidson; Gerry Lofthus; Kenneth Schnabel; Jennifer Carnahan; Lynne Shelley; Hongyue Wang Journal: Pediatrics Date: 2014-11-03 Impact factor: 7.124
Authors: Annamaria Vezzani; Robert S Fujinami; H Steve White; Pierre-Marie Preux; Ingmar Blümcke; Josemir W Sander; Wolfgang Löscher Journal: Acta Neuropathol Date: 2015-09-30 Impact factor: 17.088
Authors: Jeremy M Barry; ManKin Choy; Celine Dube; Ashlee Robbins; Andre Obenaus; Pierre Pascal Lenck-Santini; Rod C Scott; Tallie Z Baram; Gregory L Holmes Journal: Exp Neurol Date: 2015-05-01 Impact factor: 5.330
Authors: Alexander L Greninger; Samia N Naccache; Pia Pannaraj; Keith R Jerome; Jennifer Dien Bard; Jeanne W Ruderman Journal: J Clin Microbiol Date: 2019-09-24 Impact factor: 5.948
Authors: William B Gallentine; Shlomo Shinnar; Dale C Hesdorffer; Leon Epstein; Douglas R Nordli; Darrell V Lewis; L Matthew Frank; Syndi Seinfeld; Ruth C Shinnar; Karen Cornett; Binyi Liu; Solomon L Moshé; Shumei Sun Journal: Epilepsia Date: 2017-04-27 Impact factor: 5.864
Authors: Dale C Hesdorffer; Shlomo Shinnar; Darrell V Lewis; Solomon L Moshé; Douglas R Nordli; John M Pellock; James MacFall; Ruth C Shinnar; David Masur; L Matthew Frank; Leon G Epstein; Claire Litherland; Syndi Seinfeld; Jacqueline A Bello; Stephen Chan; Emilia Bagiella; Shumei Sun Journal: Epilepsia Date: 2012-06-28 Impact factor: 5.864